NOTV vs SILO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NOTV exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.30 and a Quick Ratio of 0.17, suggesting it cannot meet its short-term obligations. High leverage (Debt/Equity of 4.37) combined with stagnant revenue growth (0.80%) and consistent earnings misses creates a high risk of insolvency. The catastrophic 5-year price decline of 98.8% and bearish insider activity further confirm a negative outlook.
SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.
Compare Another Pair
Related Comparisons
NOTV vs SILO: Head-to-Head Comparison
This page compares Inotiv, Inc. (NOTV) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.